Aptinyx Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Aptinyx.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 28.3% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Aptinyx musculoskeletal pain drug NYX-2925 fails mid-stage study
Aug 12We're Keeping An Eye On Aptinyx's (NASDAQ:APTX) Cash Burn Rate
Aug 18Aptinyx: CNS Drug Discoverer With Depressed Price
Jul 21Aptinyx updates on mid-stage clinical program for PTSD therapy
Jun 15Aptinyx (NASDAQ:APTX) Is In A Good Position To Deliver On Growth Plans
Apr 13Did You Miss Aptinyx's (NASDAQ:APTX) 15% Share Price Gain?
Mar 09What Kind Of Shareholders Hold The Majority In Aptinyx Inc.'s (NASDAQ:APTX) Shares?
Jan 30Aptinyx recommences Phase 2 study of NYX-2925
Jan 04Have Insiders Been Buying Aptinyx Inc. (NASDAQ:APTX) Shares This Year?
Dec 26What Type Of Returns Would Aptinyx's(NASDAQ:APTX) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 27In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aptinyx has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2023 | N/A | -66 | -55 | -55 | N/A |
12/31/2022 | N/A | -65 | -60 | -60 | N/A |
9/30/2022 | N/A | -72 | -68 | -68 | N/A |
6/30/2022 | N/A | -78 | -68 | -68 | N/A |
3/31/2022 | N/A | -80 | -70 | -70 | N/A |
12/31/2021 | 1 | -75 | -63 | -63 | N/A |
9/30/2021 | 1 | -67 | -52 | -52 | N/A |
6/30/2021 | 1 | -57 | -47 | -47 | N/A |
3/31/2021 | 2 | -50 | -40 | -40 | N/A |
12/31/2020 | 2 | -50 | -43 | -42 | N/A |
9/30/2020 | 2 | -52 | -50 | -50 | N/A |
6/30/2020 | 3 | -56 | -48 | -48 | N/A |
3/31/2020 | 4 | -55 | -50 | -49 | N/A |
12/31/2019 | 4 | -57 | -52 | -52 | N/A |
9/30/2019 | 4 | -58 | -52 | -52 | N/A |
6/30/2019 | 4 | -57 | -53 | -53 | N/A |
3/31/2019 | 5 | -58 | -53 | -52 | N/A |
12/31/2018 | 7 | -53 | -48 | -47 | N/A |
9/30/2018 | 7 | -46 | -41 | -41 | N/A |
6/30/2018 | 7 | -40 | -38 | -37 | N/A |
3/31/2018 | 6 | -35 | -36 | -35 | N/A |
12/31/2017 | 5 | -32 | -34 | -33 | N/A |
12/31/2016 | 10 | -15 | N/A | -20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if APTX's forecast earnings growth is above the savings rate (2.2%).
Earnings vs Market: Insufficient data to determine if APTX's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if APTX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if APTX's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if APTX's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if APTX's Return on Equity is forecast to be high in 3 years time